What Samsara Biocapital, LLC reported holding on Form 13F for the quarter ended Jun 30, 2026.
CIK 1744967 · Filed Aug 14, 2026
Values are as the managers reported them, in dollars.Open the Form 13F on SEC EDGAR
| 6.3M |
| ±0% |
| $178.6M |
| 14.7% |
MLYSMineralys Therapeutics, Inc. | 5.9M | ±0% | $158.4M | 13% |
SEPNSepterna, Inc. | 3.1M | ±0% | $105.5M | 8.7% |
ALMRAlamar Biosciences, Inc. | 2.5M | New | $67.2M | 5.5% |
NGNENeurogene Inc. | 1.7M | ±0% | $54M | 4.4% |
KLRSKalaris Therapeutics, Inc. | 12.9M | −0.5% | $52.4M | 4.3% |
SGPSpyGlass Pharma, Inc. | 2.1M | ±0% | $47M | 3.9% |
STROSutro Biopharma, Inc. | 1.1M | ±0% | $35.3M | 2.9% |
IVAInventiva S.A. | 6.3M | +21.6% | $23.9M | 2% |
JBIOJade Biosciences, Inc. | 736.2K | −24.0% | $16.4M | 1.3% |
PBLSParabilis Medicines, Inc. | 556K | New | $15.2M | 1.3% |
VTVTvTv Therapeutics Inc. | 298.5K | ±0% | $11.2M | 0.9% |
AQSTAquestive Therapeutics, Inc. | 2.5M | ±0% | $10.4M | 0.9% |
NKTXNkarta, Inc. | 3.5M | ±0% | $9.9M | 0.8% |
ARTVArtiva Biotherapeutics, Inc. | 954.9K | New | $9.3M | 0.8% |
RANIRani Therapeutics Holdings, Inc. | 10.4M | +22.0% | $7.9M | 0.6% |
AGMBAgomAb Therapeutics NV | 600K | ±0% | $7.8M | 0.6% |
ABVXAbivax S.A. | 55.1K | −2.6% | $7.3M | 0.6% |
XFORX4 Pharmaceuticals, Inc | 1.4M | −23.8% | $6.5M | 0.5% |
ELOXEloxx Pharmaceuticals, Inc. | 400K | New | $5.6M | 0.5% |
CHRSCoherus Oncology, Inc. | 3.4M | ±0% | $4.8M | 0.4% |
UPBUpstream Bio, Inc. | 353.7K | −51.9% | $2.4M | 0.2% |
GOSSGossamer Bio, Inc. | 7.2M | ±0% | $1.2M | 0.1% |
